Siltuximab
- Generic Name
- Siltuximab
- Brand Names
- Sylvant
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 541502-14-1
- Unique Ingredient Identifier
- T4H8FMA7IM
- Background
Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). Its use is indicated for the treatment of...
- Indication
Siltuximab is indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. Siltuximab did not bind to virally produced IL-6 in a nonclinical study and was therefore not studied in patients with MCD who are HIV or HHV-8 positive.
- Associated Conditions
- Castleman Disease
- Associated Therapies
- -
Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia
- First Posted Date
- 2020-04-01
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Judit Pich Martínez
- Target Recruit Count
- 163
- Registration Number
- NCT04329650
- Locations
- 🇪🇸
Hospital Universitari Mútua de Terrassa, Terrassa, Spain
🇪🇸Hospital Universitario de Salamanca, Salamanca, Spain
🇪🇸Hospital Clínic de Barcelona, Barcelona, Spain
Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2017-10-19
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT03315026
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Siltuximab in Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2016-06-13
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Brian Miller
- Target Recruit Count
- 30
- Registration Number
- NCT02796859
- Locations
- 🇺🇸
Augusta University, Augusta, Georgia, United States
Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes
- First Posted Date
- 2015-12-29
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Carla Greenbaum, MD
- Target Recruit Count
- 10
- Registration Number
- NCT02641522
- Locations
- 🇺🇸
Benaroya Research Institute, Seattle, Washington, United States
Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)
- Conditions
- Interventions
- First Posted Date
- 2012-02-13
- Last Posted Date
- 2015-06-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 14
- Registration Number
- NCT01531998
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2012-01-20
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 76
- Registration Number
- NCT01513317
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2011-12-02
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 85
- Registration Number
- NCT01484275
A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease
- First Posted Date
- 2011-07-22
- Last Posted Date
- 2018-05-22
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT01400503
A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2011-03-07
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 9
- Registration Number
- NCT01309412
A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease
- Conditions
- Interventions
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2018-03-21
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 79
- Registration Number
- NCT01024036
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.